Industry News
Pharmaceutical Industry News
The FDA has rejected Hyloris…
The FDA has rejected Hyloris Pharmaceuticals' antiviral valacyclovir, an oral suspension for infections caused by herpes simplex and varicella-zoster viruses becasue of manufacturing problems.
When Weight-Loss Drugs Don’t Work
Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”
Eli Lilly is making investments in…
Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. Astellas' CEO attributed a better-than-expected reimbursement price
While much of the company’s…
While much of the company’s recent focus has remained on beefing up its U.S. infrastructure, Eli Lilly has for the second time this week made moves to raise capacity for its medicines overseas, and once
During a quarterly conference…
During a quarterly conference call, executives from Legend Biotech showed little concern for a potential threat to its lone commercial product, multiple myeloma CAR-T Carvykti. Oddly enough, the threat is coming from its Carvykti parter,
The new platform combines seven…
The new platform combines seven different adverse event dashboards into one, an effort that could save the agency $120 million over five years, it said.
According to a new team-up between…
According to a new team-up between Eisai and Pokémon, when it comes to healthy sleep habits, people of all ages have gotta catch ’em all.
Eli Lilly—which has already…
Eli Lilly—which has already staged multiple efforts in court to protect sales of its diabetes and obesity meds Mounjaro and Zepbound from compounders—is launching a new salvo focused on the potential safety risks behind a
The rare disease field is…
The rare disease field is navigating a period of significant turbulence, what with a “temperamental” FDA and competition for investor attention from mainstream blockbusters like obesity treatments. Yet, despite the “stormy waters,” global sales of
As AstraZeneca kicks off the third…
As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice.
Eli Lilly continued staggering…
Eli Lilly continued staggering sales growth in the fourth quarter, nearly tripling that of any other top 25 drugmaker. Meanwhile, most companies are expecting a slowdown in growth in 2026.
Veeva Systems, which offers life…
Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro.
Point-of-care marketing promises…
Point-of-care marketing promises conversion, but many strategies miss the prescribing moment. Are these common assumptions undermining your results?
The $3 billion investment will…
The $3 billion investment will take shape over the next ten years, the company said, and will increase the global supply of its oral GLP-1 prospect orforglipron.
After strutting its stuff against…
After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis in a head-to-head phase 3b study.
Johnson & Johnson CEO Joaquin…
Johnson & Johnson CEO Joaquin Duato has been awarded nearly $32.8 million in 2025 pay, marking a significant leap over the $24.3 million he was granted for 2024.
Skyhawk Therapeutics has named…
Skyhawk Therapeutics has named Aaron Deves as chief commercial officer, securing the expertise of an executive who oversaw products including Austedo while at Teva. The company shared the news the same day Santhera Pharmaceuticals revealed
Biopharma companies are signaling…
Biopharma companies are signaling a tougher year ahead. As patent protections expire and growth slows across the industry, only a handful of drugmakers expect bigger gains in 2026.
Sandoz is committing even further…
Sandoz is committing even further to its biosimilar business with plans to launch a dedicated unit that will operate separately from the company’s remaining small molecule generics division.
In his second year as CEO,…
In his second year as CEO, AbbVie's Robert Michael received a $32.5 million pay package, a hefty raise from his 2024 pay of $18.5 million.